

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6378430

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MUNDIPHARMA EDO GMBH	06/08/2018
RECEIVING PARTY DATA	
Name:	PURDUE PHARMACEUTICAL PRODUCTS L.P.
Street Address:	ONE STAMFORD FORUM, 201 TRESSER BLVD
City:	STAMFORD
State/Country:	CONNECTICUT
Postal Code:	06901
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	16621885
Application Number:	16621893
Application Number:	16621896
Application Number:	16621898
CORRESPONDENCE DATA	
Fax Number:	(617)607-9200
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 449-6523
Email:	oquiterio@mccarter.com
Correspondent Name:	MCCARTER & ENGLISH, LLP
Address Line 1:	265 FRANKLIN STREET
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	132179-00301
NAME OF SUBMITTER:	YU LU, PH.D.
SIGNATURE:	/Yu Lu/
DATE SIGNED:	10/30/2020
Total Attachments: 8	
source=P1442 Assignment - Mundi EDO to PPPLP (US only)#page1.tif	
source=P1442 Assignment - Mundi EDO to PPPLP (US only)#page2.tif	
source=P1442 Assignment - Mundi EDO to PPPLP (US only)#page3.tif	

source=P1442 Assignment - Mundi EDO to PPPLP (US only)#page4.tif
source=P1442 Assignment - Mundi EDO to PPPLP (US only)#page5.tif
source=P1442 Assignment - Mundi EDO to PPPLP (US only)#page6.tif
source=P1442 Assignment - Mundi EDO to PPPLP (US only)#page7.tif
source=P1442 Assignment - Mundi EDO to PPPLP (US only)#page8.tif

YINBA, MUDY, NUM, CHUN
PUD, CUBA, PABE

DATED

2018

(1) MUNDIPHARMA EDO GMBH

- and -

(2) PURDUE PHARMACEUTICAL PRODUCTS L.P.

ASSIGNMENT OF PATENT APPLICATIONS AND
RELATED US RIGHTS

Ref: MC928087WO

THIS DEED OF ASSIGNMENT is made the day of 2018

BETWEEN

- (1) Mundipharma EDO GmbH, a Swiss company whose principal place of business is at St. Alban Rheinweg 74, CH-4020 Basel, Switzerland (the "Assignor"); and
- (2) Purdue Pharmaceutical Products L.P., a Delaware limited partnership whose principal place of business is at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901, USA (the "Assignee").

RECITALS

- (A) The Assignor has filed certain patent applications ("the Applications"), further particulars of which are given in the Schedule, in respect of the Inventions respectively disclosed in the Applications ("the Inventions").
- (B) The Assignor has agreed to assign to the Assignee the Inventions and the Applications and all its rights, title and interest therein upon the terms and conditions set out below.

OPERATIVE PROVISIONS

- I. In consideration of the sum of £1 paid by the Assignee to the Assignor (the receipt and sufficiency of which the Assignor hereby acknowledges) the Assignor with full title guarantee HEREBY ASSIGNS unto the Assignee:
 - (a) the Inventions and the full and exclusive benefit of them in the US;
 - (b) all the rights of the Assignor in and to the Applications and the full and exclusive benefit of them and all rights privileges and advantages associated with them in the US;
 - (c) the full right to apply for and obtain patents or other similar forms of protection in respect of the Inventions in the US;

- (d) the right to make any new application or applications in the US in respect of any part or parts of the subject matter of any application or specification filed in connection with the Inventions;
- (e) any patents or other similar forms of protection granted in respect of the Inventions pursuant to the Applications in the US;
- (f) the right to claim priority of the Applications in the US; and
- (g) the right to bring proceedings in the US for the recovery of damages and/or other remedies in respect of any previous infringement of the rights assigned by this Assignment.

TO HOLD the same unto the Assignee absolutely.

2. The Assignor undertakes that it will not without the consent of the Assignee publish or disclose any particulars of the Inventions or the Applications to any person.
3. The Assignor hereby covenants with the Assignee that it shall execute such further documents and do such further acts, and shall procure on the part of the inventors of the Inventions the execution and doing of all such further documents and acts, as may reasonably be required by the Assignee to enable the Assignee (or its nominee) to enjoy the full benefit of the property and rights hereby assigned and to apply for any patents or other forms of protection in respect of the Inventions throughout the world, and fully and effectively to vest the same in the Assignee or as the Assignee shall direct.
4. The Assignor further covenants with the Assignee that at the request and expense of the Assignee it shall provide all such assistance as the Assignee may reasonably require in connection with any proceedings concerning the Applications or any patents, patent applications or similar rights applied for or arising in respect of the Inventions, including the disclosure of relevant documents and materials and the provision of oral and written testimony from relevant personnel.

5. This Assignment shall be governed by and construed in accordance with English law and shall be subject to the exclusive jurisdiction of the English courts.

IN WITNESS of which this Assignment has been executed as a Deed and delivered the date and year first above written.

SCHEDULE

Patent Applications

Reference	Application Number	Date Filed	Subject Matter	Designated States (PCT)
PC928106 P1422-GB-1	1709402.0	13-06-2017	Treatment of T-PLL	
P1422-WO-1				US only
PC928255 P1437-GB-1	1709403.8	13-06-2017	Compounds for treating sarcoma	
P1437-WO-1				US only
PC928271 P1442-GB-1	1709406.1	13-06-2017	Compounds for treating TNBC	
P1442-WO-1				US only
PC928257 P1439-GB-1	1709405.3	13-06-2017	Compounds for treating ovarian cancer	
P1439-WO-1				US only
PC928187 P1440-GB-1	1709544.9	15-06-2017	Compounds for treating vasculitis	
P1440-WO-1				US only
PC928189 P1441-GB-1	1709559.7	15-06-2017	Compounds for treating lupus erythematosus	
P1441-WO-1				US only

PC928179 P1436-GB-1	1715404.8	22-9-2017	Improved Process for the Preparation of a Formulation	
P1436-WO-1				US only

SIGNED as a deed by
MUNDIPHARMA EDO GMBH
acting by Thomas Mehrling, a
director

Signature: Thomas Mehrling

Date: 8. June 2018

In the presence of:

Signature of witness: D. Trunz

Name of witness: Dagmar Trunz

Address of witness: Mundipharma Edo GmbH Basel

Occupation of witness: Executive Team Coordinator

Date: June 8, 2018

SIGNED as a deed by
PURDUE PHARMACEUTICAL PRODUCTS L.P.
acting by Stuart D. Baker, a general partner:

Signature:

Date:

In the presence of:

Signature of witness:

Name of witness:

Address of witness:

Occupation of witness:

Date:

SIGNED as a deed by
MUNDIPHARMA EDO GMBH
acting by Thomas Mehrling, a
director

Signature:

Date:

In the presence of:

Signature of witness:


Name of witness:

Address of witness:

Occupation of witness:


Date:

SIGNED as a deed by
PURDUE PHARMACEUTICAL PRODUCTS L.P.
acting by Stuart D. Baker, a general partner:

Signature: 

Date: June 8, 2018

In the presence of:

Signature of witness: 

Name of witness: Susy Evans

Address of witness: 201 Tresser Boulevard, Stamford CT 06901

Occupation of witness: Administrative Associate

Date: June 8, 2018